Company: RGNT
Filing Date: 2025-07-07
Form Type: F-1/A
Source: 0001213900-25-061821
Chunk: 91

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-07-07
Form: F-1/A
Chunk 91
---
 disease states or indications we may pursue; |

| ● | existing regulations and                                              
 regulatory developments in the United States and other jurisdictions; |

| ● | our plans and ability to                                                                                                                 
 obtain or protect intellectual property rights, including extensions of patent terms where available and our ability to avoid infringing 
 the intellectual property rights of others;                                                                                              |

| ● | the need to hire additional                                     
 personnel and our ability to attract and retain such personnel; |

| ● | our estimates regarding                                                            
 expenses, future revenue, capital requirements and needs for additional financing; |

| ● | our dependence on third 
 parties;                |

| ● | our financial performance                     
 and our ability to repay our loans and debts; |

| ● | the period over which we                                                                                                         
 estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure 
 requirements;                                                                                                                    |

| ● | our ability to generate                                                                      
 revenue and profit margin under our anticipated contracts which is subject to certain risks; |

| ● | difficulties in our and                                                                                                          
 our partners’ ability to recruit and retain qualified physicians and other healthcare professionals, and enforce our non-compete 
 agreements with our physicians;                                                                                                  |

<div align='center'>56</div>

| ● | our ability to restructure                                             
 our operations to comply with future changes in government regulation; |

| ● | our ability to address                                                                                                            
 any competing technological and market developments that impact our Gelrin hydrogel platform and any future product candidates or 
 their prospective usage by medical professionals;                                                                                 |

| ● | our ability to negotiate                                                                                                             
 favorable terms in any collaboration, licensing or other arrangements into which we may enter and perform our obligations under such 
 collaborations;                                                                                                                      |

| ● | our ability to maintain,                                                                                                              
 protect and expand our portfolio of intellectual property rights, including patents, patent applications, trade secrets and know-how; |
| ● | our expectations regarding                                                                                                            
 having our Ordinary Shares listed on the NYSE American;                                                                               |

| ● | our anticipated use of                   
 the net proceeds from this offering; and |

| ● | statements as to the impact                                                                                                            
 of the political and security situation in Israel on our business, including due to war or conflicts between Israel, Hamas, Hezbollah, 
 and on other fronts from various extremist groups in the region, such as the Houthis in Yemen and various rebel militia groups in      
 Syria and Iraq.                                                                                                                        |

Forward-looking statements
are based on our management’s current expectations, estimates, forecasts and projections